FDA’s second OK of the day, third in 24 hours | To view this email as a web page,
click here Breaking News | | | Friday, August 16, 2019 The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here. Friday, the FDA green-lighted Rinvoq, a rheumatoid arthritis med meant to succeed best-selling Humira as copycats bite into its sales. The new product should be available in the U.S. by late August, AbbVie said. |
|
|
| | | Friday, August 16, 2019 Bristol-Myers Squibb’s $74 billion Celgene takeover has been a roller coaster, with some Revlimid patent wins on the upside and, on the down, an FTC-forced sale of blockbuster Otezla. But the FDA just handed the merger partners another win. |
|
|
| | | Thursday, August 15, 2019 Roche’s targeted cancer drug Rozlytrek officially has its U.S. green light—and in not just one, but two cancer types. Thursday, the FDA cleared the med to treat ROS1-positive non-small cell lung cancer and tough-to-treat NTRK fusion-positive tumors. |
|
|
|
|
